

National Cancer Institute
Institutional Review Board

AGENDA

November 4, 2013

1:00 – 5:00 pm

CRC/3-1608

- 1. Review of Draft Minutes, October 21, 2013**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
 - **CTEP vs CCR Consent Template**
- 5. NIH Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews/Terminations**
- 8. Amendment** 12C0159C, "Effects of Antimicrobial Treatments on the Microbiome in Healthy Volunteers and Patients with Atopic Dermatitis" - Heidi Kong, PI
- 9. Amendment** 11C0102J, "A Phase I/II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (HCC)" - Tim Greten, PI
- 10. Amendment** 13C0093D, "Phase II Study in Patients with Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes with or without High Dose Aldesleukin" - Udai Kammula, PI
- 11. Amendment** 13C0152B, "A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors"—Melinda Merchant, PI